Structure Therapeutics Inc. (GPCR) intrinsic value & 10-year financials
Structure Therapeutics Inc. (GPCR) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $21.08
- Market cap
- $3.7B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -7.2%
- Free cash flow (FY2025)
- -$225.8M
GPCR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$141.2M | -$0.80 | -$225.8M | — | -24.9% |
| FY2024 | — | -$122.5M | -$0.78 | -$117.9M | — | -30.9% |
| FY2023 | — | -$89.6M | -$0.81 | -$81.7M | — | -31.4% |
| FY2022 | — | -$51.3M | -$0.50 | -$46.3M | — | 58.4% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Structure Therapeutics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Structure Therapeutics Inc. has historically struggled to out-earn its cost of capital, averaging just -7.2% ROIC.
Structure Therapeutics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Structure Therapeutics Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.